Tissue-targeted Immune Modulation

EUPRAXIA PHARMACEUTICALS is a clinical-stage biotechnology company
leveraging proprietary and innovative Diffusphere™ delivery technology with the
goal of providing
the right dose of drug in the
right place for the
right amount of time
in indications with a high unmet medical need

Our Technology

About Eupraxia Pharmaceuticals


Our Team

Eupraxia is proud of its experienced team of life science professionals.

Learn More


Our Lead Candidate

EP-104 is designed to address significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE).

Learn More


Our Pipeline

Our technology platform may be suitable for a wide range of indications and drugs that could be improved by locally targeted and extended release.

Learn More

View all news

Latest News